Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurigene Discovery Technologies Ltd.

Division of Dr. Reddy's Laboratories Ltd.
www.aurigene.com

Latest From Aurigene Discovery Technologies Ltd.

2018 Preparation: PD-1 Predictions And Commercialization Challenges

What's next for the PD-1 market, a cancer therapy area that exploded in 2017 as recently launched products secured ever more approvals? Maria Whitman, managing principal at sales and marketing firm ZS Associates, talks about challenges facing the booming immuno-oncology market and shares her predictions for 2018.

ImmunoOncology Business Strategies

Deals Shaping The Medical Industry, May 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2017.

Deals BioPharmaceutical

Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.

Deals M & A

Enumeral Biomedical Holdings Inc.

Checkpoint inhibitors have caused a sensation in oncology in recent years, but biotech Enumeral Biomedical Holdings Inc. is setting its sights on the Achilles' heel of the new antibodies – the high failure rate – using a discovery platform that employs cells from human biopsies, rather than more commonly used rodent models.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Dr. Reddy's Laboratories Ltd.
  • Senior Management
  • CSN Murthy, CEO
    Ashish Lath, Dir., Finance
    Murali Ramachandra, PhD, CSO
  • Contact Info
  • Aurigene Discovery Technologies Ltd.
    Phone: (91) 80 7102 5444
    39-40, KIADB Industrial Area, Hosur Rd.
    Bangalore, 560 100
    India
Advertisement
Advertisement
UsernamePublicRestriction

Register